A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia.
Giles F, Thomas D, Garcia-Manero G, Faderl S, Cortes J, Verstovsek S, Ferrajoli A, Jeha S, Beran M, Koller C, Andreeff M, Cahill A, Clairmont C, Sznol M, Kantarjian H.
Giles F, et al. Among authors: beran m.
Clin Cancer Res. 2004 May 1;10(9):2908-17. doi: 10.1158/1078-0432.ccr-03-0738.
Clin Cancer Res. 2004.
PMID: 15131024
Clinical Trial.